Compare Bristol-Myers Squibb Co (BMY) vs Global X Autonomous & Electric Vehicles (DRIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Global X Autonomous & Electric Vehicles — how do they compare? Bristol-Myers Squibb Co trades at $63.95 (market cap $129.94B), while Global X Autonomous & Electric Vehicles trades at $36.14. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Global X Autonomous & Electric Vehicles pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Global X Autonomous & Electric Vehicles nearer its low. Which is the better fit depends on your goals.
| BMY | DRIV | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $65.89 | $42.53 |
52-Week Low | $42.60 | $25.23 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
DRIV trades at $36.14, up 1.6% today, with technical indicators showing a bullish trend supported by moving averages, though RSI suggests potential overbought conditions. The stock's support and resistance levels are tightly clustered around $35-$36. Recent news highlights strong global EV sales growth, particularly in Europe and China, driven by rising fuel prices and supportive policies, which may benefit DRIV's sector exposure.
The outlook for DRIV is positive due to favorable industry trends, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed, with technical strength offset by valuation concerns. Investors should weigh growth potential against execution risks in the evolving EV market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →
